Skip to main content
. 2021 Sep 21;12:723609. doi: 10.3389/fimmu.2021.723609

Table 1.

Prospective clinical trials evaluating PD-1/PD-L1 blockades combining with RT in NSCLC.

Trial Phase Stage N sequence ICI Agent RT Dose OS PFS Toxicity≥G3(%)
PACIFIC (49, 50) III Locally advanced Unresectable III 713 CRT> ICI vs. CRT>placebo Durvalumab (10 mg per kilogram of body weight intravenously every 2 weeks) 54-66Gy 1-yr: 83.1% vs.74.6% Median 17.2 vs. 5.6 months 30.5% vs. 26.1%
2-yr: 66.3% vs. 55.3%
HCRN LUN 14 -179 (51) II Locally advanced Unresectable IIIA/B 92 CRT> ICI Pembrolizumab (200 mg intravenously every 3 weeks) 59.4-66.6Gy 1-yr: 81.2% Median 18.7months 4.30%
2-yr: 62.0%
3-yr: 48.5%
DETERRED (52) II Locally advanced Unresectable III 40 CRT+ICI>CT+ICI vs. CRT>CT+ICI atezolizumab (1200 mg IV Q3 weeks) 60-66Gy/30-33 fractions 1-yr: 60% vs. 77% Median 20.1 months vs. NR 1-yr:60% vs. 66% 57%
ETOP NICOLAS (53) II Locally advanced Unresectable IIIA/B 79 CRT+ICI> ICI Nivolumab (360 mg every three weeks for the first four doses, followed by 480 mg every four weeks) 66 Gy/33fractions NR NR 10% for pneumonitis
PEMBRO -RT (42) II metastatic IV 74 SBRT (single tumor site)> ICI vs. ICI Pembrolizumab (200mg every three weeks) 24Gy/3fractions Median 15.9 vs. 7.6months Median 6.6 vs. 1.9months 17% vs. 22%

RT, radiotherapy; CRT, chemoradiotherapy; CT, chemotherapy; SBRT, stereotactic body radiotherapy; ICI, immune checkpoint inhibitors; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; NR, not reported.